Exploratory objectives included an evaluation of tumor volume measured using MRI pre-pembrolizumab versus post-pembrolizumab therapy, as well as an evaluation of markers of apoptosis (cleaved caspase 3) and proliferation (Ki67), pre-therapy versus post-therapy. The gene discussed is CASP3; the disease is neoplasm.